In the future, we hope to do corresponding cell or animal experiments to assess the impact of ATOH1 on the COAD immune microenvironment and to specify the detailed mechanism underlying the effectiveness of ICI therapy. The gene discussed is ATOH1; the disease is colon adenocarcinoma.